Bristol Myers Squibb

"2023 DEI Employer® Awards" Winners and the List of "2023 Top 50 DEI Employer®" Officially Announced in China

Retrieved on: 
Thursday, January 4, 2024
Multimedia, Research, Employer branding, ESG, HR, University, DEI, HSBC Bank (China), CSRD, Bristol Myers Squibb

SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- The winners of the "2023 DEI Employer® Awards (China)" hosted by the Employer Branding Institute, a leading employer brand communication organization, are grandly announced.

Key Points: 
  • SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- The winners of the "2023 DEI Employer® Awards (China)" hosted by the Employer Branding Institute, a leading employer brand communication organization, are grandly announced.
  • This award conducted a comprehensive evaluation of 10 categories, 21 dimensions, and 104 indicators of companies' DEI practices.
  • On December 18, "2023 DEI Employer® Awards (China)" award ceremony, sponsored by the global premium spirits brand REMY COINTREAU, was held grandly in Kunming, Yunnan.
  • On December 27, 2023, the Employer Branding Institute officially released the list of "2023 Top 50 DEI Employer® in China".

"2023 DEI Employer® Awards" Winners and the List of "2023 Top 50 DEI Employer®" Officially Announced in China

Retrieved on: 
Thursday, January 4, 2024
Research, Employer branding, ESG, HR, University, DEI, HSBC Bank (China), CSRD, Bristol Myers Squibb

SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- The winners of the "2023 DEI Employer® Awards (China)" hosted by the Employer Branding Institute, a leading employer brand communication organization, are grandly announced.

Key Points: 
  • SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- The winners of the "2023 DEI Employer® Awards (China)" hosted by the Employer Branding Institute, a leading employer brand communication organization, are grandly announced.
  • This award conducted a comprehensive evaluation of 10 categories, 21 dimensions, and 104 indicators of companies' DEI practices.
  • On December 18, "2023 DEI Employer® Awards (China)" award ceremony, sponsored by the global premium spirits brand REMY COINTREAU, was held grandly in Kunming, Yunnan.
  • On December 27, 2023, the Employer Branding Institute officially released the list of "2023 Top 50 DEI Employer® in China".

Debbie's Dream Foundation: Curing Stomach Cancer Celebrates a Year of Impactful Programs and Community Support in 2023

Retrieved on: 
Wednesday, January 3, 2024
Veteran, Stomach, Travel, Amgen, ASCO, Caregiver, DDF, Daiichi Sankyo, Research, Zymeworks, DSI, Copper, Stomach cancer, Federation, Genetics, BMS, United Way, Mind, Patient, Medicine, Bristol Myers Squibb, Club, Pharmaceutical industry

FORT LAUDERDALE, Fla., Jan. 3, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) proudly wraps up an impactful year, delivering crucial resources and support to the stomach cancer community, thanks to the unwavering commitment of 2023 industry partners. The support from generous sponsors has allowed DDF to continue vital programs and initiate new endeavors. This year, DDF worked closely with sponsors such as Amgen, Arcus, Astellas, Bristol Myers Squibb (BMS), Daiichi Sankyo (DSI), Genentech, Lilly Oncology, Merck, Taiho Oncology, and Zymeworks, whose dedication has been instrumental in advancing various programs, ensuring DDF's continued service to patients, their families, and caregivers.

Key Points: 
  • FORT LAUDERDALE, Fla., Jan. 3, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) proudly wraps up an impactful year, delivering crucial resources and support to the stomach cancer community, thanks to the unwavering commitment of 2023 industry partners.
  • The support from generous sponsors has allowed DDF to continue vital programs and initiate new endeavors.
  • At the top of the year, DDF hosted its Inaugural Patient Advocate Retreat during its 11th Annual Stomach Cancer Capitol Hill Advocacy Day in Washington, D.C.
  • For the 2023 Symposia series, DDF collaborated with Moffitt Cancer Center in Tampa, Florida, to host a Stomach Cancer Educational Symposium.

Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, January 3, 2024
IO, Biology, Research, Bristol Myers Squibb, Disease, Merck Serono, Therapy, Merkel-cell carcinoma, Cancer, Molecular biology, Master of Science, Novartis, M.A, Biochemistry, Proteomics, Neoplasm, Serono, Merck, Ipilimumab, AP3, Patient, ACRV, Medicine, Phase II, Pharmacology, Pharmaceutical industry

WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Jean-Marie Cuillerot, M.D., as chief medical officer.

Key Points: 
  • WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Jean-Marie Cuillerot, M.D., as chief medical officer.
  • “Jean-Marie has over twenty years of successful experience in oncology drug development, and we are delighted to have him join Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • “During his impressive career, he has effectively executed on advancing drugs from early development through regulatory approval, at both pharma and biotech companies.
  • Prior to Dragonfly, Dr. Cuillerot was the chief medical officer of Agenus, where he led development activities for five investigational therapies.

Epigenetic Therapeutics Global Markets Research 2023-2028 Featuring Major Players - AstraZeneca, Bristol-Myers Squibb, GSK, Ipsen, Seagen, and Incyte - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 2, 2024
Pharmaceutical, Health, Oncology, AstraZeneca, Breast cancer, Ovarian cancer, IDH, Prevalence, Bristol Myers Squibb, HDAC, Cancer, GSK, Epigenomics, COVID-19, Ageing, KMT, Growth, Row, DNMT, Environment, Pharmaceutical industry

The global epigenetic therapeutics market was valued at $6.4 billion in 2022.

Key Points: 
  • The global epigenetic therapeutics market was valued at $6.4 billion in 2022.
  • Technological innovations in epigenetic drug discovery and development are driving increased use of epigenetic therapeutics, which also is pushing market growth.
  • This report is a comprehensive study of the global market for epigenetic therapeutics.
  • This report examines the factors driving growth in the epigenetic drugs market, and it reviews major players, established companies and new entrants.

The top 25 Best Places to Work in Europe for 2023 revealed

Retrieved on: 
Tuesday, January 2, 2024
Research, Bristol Myers Squibb, Organization, Agility, Takeda

LONDON, UK - Media OutReach Newswire - 2 January 2024 - The Best Places to Work organization announced today the top 25 Best Places to Work in Europe for 2023.

Key Points: 
  • LONDON, UK - Media OutReach Newswire - 2 January 2024 - The Best Places to Work organization announced today the top 25 Best Places to Work in Europe for 2023.
  • McDonald’s secured the third among the top 25 most performing organizations in Europe.
  • For the past couple of years, the Best Places to Work program has recognized leading employers across the world, backed by several years of workplace culture assessment and a global database of over 25 million employees.
  • To be considered for the list, companies must be identified as outstanding employers at least in one of the countries in Europe.

European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors

Retrieved on: 
Tuesday, January 2, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, BMY, Lung cancer, Food, EMA, ROS1, Brain, Therapy, TKI, Clinical trial, Metastasis, Neoplasm, European Medicines Agency, CARE, NTRK, Bristol Myers Squibb, Patient, NSCLC, Pharmaceutical industry

The application was based on results from the registrational Phase 1/2 TRIDENT-1 trial (adult patients with ROS1-positive NSCLC or NTRK-positive solid tumors) and CARE study (pediatric patients with NTRK-positive solid tumors).

Key Points: 
  • The application was based on results from the registrational Phase 1/2 TRIDENT-1 trial (adult patients with ROS1-positive NSCLC or NTRK-positive solid tumors) and CARE study (pediatric patients with NTRK-positive solid tumors).
  • The study remains ongoing to assess long-term outcomes and additional endpoints across patient populations with ROS1-positive locally advanced or metastatic NSCLC and NTRK-positive locally advanced or metastatic solid tumors.
  • Additionally, in November 2023 the U.S. Food and Drug Administration approved Augtyro™ (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC.
  • As of August 2022, Bristol Myers Squibb acquired the company, including its asset repotrectinib.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, GRCL, RYZB, BRBS

Retrieved on: 
Monday, January 1, 2024
ADS, Blue, Sale, AstraZeneca, Daseke, BRB, Bristol Myers Squibb, Fraud, Advertising, Security (finance)

If you are a Daseke shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Daseke shareholder, click here to learn more about your rights and options .
  • If you are a Gracell shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PGTI, AYX, KRTX, THRX

Retrieved on: 
Monday, January 1, 2024
Insight Partners, Alteryx, Sale, PGT, Therapy, Fraud, Advertising, Masonite International, Bristol Myers Squibb, Security (finance)

If you are a PGT shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a PGT shareholder, click here to learn more about your rights and options .
  • If you are an Alteryx shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX

Retrieved on: 
Sunday, December 31, 2023
Class Action Lawsuit, Professional Services, Legal, BMY, Bristol Myers Squibb, KSF, Sale, KRTX, Therapy

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna Therapeutics, Inc. (NasdaqGM: KRTX) to Bristol-Myers Squibb Company (NYSE: BMY).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna Therapeutics, Inc. (NasdaqGM: KRTX) to Bristol-Myers Squibb Company (NYSE: BMY).
  • Under the terms of the proposed transaction, shareholders of Karuna will receive $330.00 in cash for each share of Karuna that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .